21 Jun

Array BioPharma: Why Wall Street Analysts Are Positive

WRITTEN BY Daniel Collins FEATURED IN Company News, Insights, & Analysis

Stock performance

On June 20, Array BioPharma’s stock price grew 5.2% and reached $19.99 from its close of $19.0 the previous day. On June 20, Array BioPharma hit its 52-week high of $20.18.

On June 19, Array BioPharma’s stock price grew ~8.6% to ~$19.00 from its close of $17.50 on June 18.

On June 20, Array BioPharma’s stock price closed at $19.99, which represents ~180% growth from its 52-week low of $7.15 on August 3, 2017.

Recent developments

In June, Array BioPharma (ARRY) provided updated results from the phase 3 COLUMBUS trial. The trial evaluated the safety and efficacy of encorafenib and binimetinib in treating individuals with BRAF-mutant advanced melanoma.

In the COLUMBUS clinical trial, patients receiving the encorafenib and binimetinib combination therapy showed a median overall survival of 33.6 months—compared to 16.9 months for patients receiving Roche’s Zelboraf (vemurafenib) monotherapy. The encorafenib and binimetinib combination therapy demonstrated a two-year survival of 58%.

Previously, Array BioPharma reported that patients receiving the encorafenib and binimetinib combination therapy demonstrated PFS (progression-free survival) of 14.9 months—compared to 7.3 months for patients receiving vemurafenib. Array BioPharma noted that the updated median PFS remained consistent with the previously reported median PFS.

Array BioPharma: Why Wall Street Analysts Are Positive

Analysts’ recommendations

Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”

On June 20, Array BioPharma had a consensus 12-month target price of $21.38, which represents an ~7% return on investment over the next 12 months.

Peers’ ratings

Of the nine analysts tracking Halozyme Therapeutics (HALO) in June, ~44% recommended a “buy.” Among the 11 analysts tracking Aerie Pharmaceuticals (AERI), ~91% recommended a “buy.” Of 16 analysts tracking Intercept Pharmaceuticals (ICPT) in June, ~44% recommended a “buy.”

On June 20, Halozyme Therapeutics, Aerie Pharmaceuticals, and Intercept Pharmaceuticals had consensus 12-month target prices of $20.56, $82.3, and $106.69, respectively, which represents a return on investment of ~5.60%, ~24.9%, and ~25.3% over the next 12 months.

Latest articles

Monster Beverage (MNST) stock was down 1.6% as of 2:47 PM EDT on March 20.

Earlier today, the second-largest US automaker by 2018 sales volume, Ford Motor Company (F), revealed its plan to invest $850 million in its Flat Rock assembly plant through 2023.

Mizuho downgraded Yum! Brands (YUM) from “neutral” to “underperform” while keeping its 12-month price unchanged at $84, which represents a fall of 15.4% from its March 19 closing price of $99.20.

20 Mar

Why Verizon Sought to Lead 5G Rollout

WRITTEN BY Rachel Gunter

According to Verizon, its mobile 5G plans will cost $10 more than its current 4G plans.

As of March 19, Dunkin’ Brands (DNKN) was trading at $71.55, which represents a rise of 3.9% since the announcement of its fourth-quarter earnings on February 7.

Suncor Energy's shareholder returns have grown consistently over the past few years. The company hasn't forgotten its commitment to growth.